within Pharmacolibrary.Drugs.ATC.R;

model R05DB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.6666666666666666,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.1,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Benzonatate is a non-narcotic antitussive (cough suppressant) used in the symptomatic treatment of cough. It is structurally related to para-aminobenzoic acid, acts by anesthetizing stretch receptors in the respiratory passages, lungs and pleura, and is approved for use in the United States.</p><h4>Pharmacokinetics</h4><p>No formal population pharmacokinetic data are published for benzonatate in humans. The following estimated parameters are based on limited data from official product labels and drug monographs, which state rapid absorption and onset of action (15-20 minutes) and duration of effect (3-8 hours) after a typical adult dose.</p><h4>References</h4><ol><li><p>Man, J, Jiao, F, Wang, Y, Gu, Y, Ding, L, &amp; Shu, C (2019). Determination of benzonatate and its metabolite in human plasma by HPLC-MS/MS: A preliminary pharmacokinetic study in healthy Chinese volunteers after oral administration of benzonatate soft capsule. <i>Journal of pharmaceutical and biomedical analysis</i> 173 134â€“143. DOI:<a href=&quot;https://doi.org/10.1016/j.jpba.2019.05.030&quot;>10.1016/j.jpba.2019.05.030</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31129533/&quot;>https://pubmed.ncbi.nlm.nih.gov/31129533</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R05DB01;
